LLS Phone Education Programs for September
In September the Leukemia & Lymphoma Society will be continuing its free telephone education program with two teleconferences:
Chronic myelogenous leukemia
The first teleconference will be on September 15, 2009 starting at 12 PM Eastern entitled:
CML: What Every Newly Diagnosed Patient Needs to Know
The program will feature Jorge Cortes MD, a Professor of Medicine, Chief, CML Section, Department of Leukemia at one of the top cancer centers in the United States, the University of Texas MD Anderson Cancer Center in Houston Texas.
More information on this program and a link to register can be found here.
Non-Hodgkin's Lymphoma
Then on September 22, 2009 the LLS will offer:
Emerging Therapies in NHL: Understanding Your Options
The program will feature Andrew D. Zelenetz, MD, PhD, Chief, Lymphoma Service, Division of Hematology/Oncology, Dept of Medicine, at another one of the elite cancer centers in the US, Memorial Sloan-Kettering Cancer Center, New York NY.
More information on this program and a link to register can be found here.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
